Arsenal Medical Stock
Arsenal Medical develops novel products that improve local therapy for injuries and diseases.
Sign up today and learn more about Arsenal Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Arsenal Medical Stock
Arsenal Medical uses conventional biomaterials in unconventional ways to develop novel products that improve local therapy for injury and disease. The company is advancing multiple preclinical programs based on both its two proprietary technology platforms: its therapeutic foam and AxioCore, a novel, high-throughput nanofiber technology. Arsenal Medical is supported by venture funding, as well as grants from the Department of Defense, National Institute of Standards and Technology’s Technology Innovation Program (NIST-TIP) and the Bill & Melinda Gates Foundation. Its investors include Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners.
Funding History
| April 2009 | $8.2M |
|---|---|
| January 2010 | $2.0M |
| January 2010 | $2.0M |
| March 2010 | $1.0M |
| May 2010 | $10.0M |
| August 2010 | $3.0M |
| September 2011 | $3.0M |
| October 2012 | $3.0M |
| August 2013 | $4.0M |
| June 2015 | $16.0M |
Management
President and CEO
R. Scott Rader
Founder and Chairman
Carmichael Roberts
President and Chief Executive Officer
James J. Barry
Co-Founder
Robert Langer
Director of Materials Science and Engineering
Upma Sharma
Vice President, Research and Development
Toby Freyman
EVP & COO
James J. Barry
Press
patents - Apr, 13 2024
Embolic compositions and methodspatents - Apr, 13 2024
In situ forming hemostatic foam implantspatents - Apr, 13 2024
In situ forming hemostatic foam implantspatents - Apr, 13 2024
Delivery system for in situ forming foams and methods of using the samepatents - Apr, 13 2024
Methods, devices and systems for filling body cavitiesEquityZen Recognized As:
